Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Renata Bezděková"'
Autor:
Romana Bútová, Petra Vychytilová-Faltejsková, Jana Gregorová, Lenka Radová, Martina Almáši, Renata Bezděková, Lucie Brožová, Jiří Jarkovský, Zdeňka Knechtová, Martin Štork, Luděk Pour, Sabina Ševčíková
Publikováno v:
Biomedicines, Vol 9, Iss 11, p 1637 (2021)
Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Due to modern genomic techniques, the involvement of lncRNAs in tumorigenesis has been revealed; however, information concerning lncRNA interplay in multiple myeloma (MM)
Externí odkaz:
https://doaj.org/article/f43e6c946a264e1f92f59c50de106207
Autor:
Lucie Říhová, Romana Králová, Pavel Coufal, Pavel Polák, Břetislav Lipový, Renata Bezděková, Andrea Štěpařová, Jiřina Zavřelová, Lukáš Frola, Hana Krupicová, Miroslav Penka, Marie Prudková, Yvona Kaloudová
Publikováno v:
Vnitřní lékařství. 66:242-248
Heparin-induced thrombocytopenia (HIT) is an immunologically-mediated complication, which usually follows heparin exposition, less frequently exposition to other drugs or even occurs spontaneously. The type of heparin, its dose and mode of applicatio
Autor:
Martina Almáši, Lucie Brožová, Renata Bezděková, Lenka Radová, Jiří Jarkovský, Luděk Pour, Sabina Ševčíková, Zdeňka Knechtová, Jana Gregorová, Petra Vychytilova-Faltejskova, Romana Bútová, Martin Stork
Publikováno v:
Biomedicines
Volume 9
Issue 11
Biomedicines, Vol 9, Iss 1637, p 1637 (2021)
Volume 9
Issue 11
Biomedicines, Vol 9, Iss 1637, p 1637 (2021)
Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Due to modern genomic techniques, the involvement of lncRNAs in tumorigenesis has been revealed
however, information concerning lncRNA interplay in multiple myeloma
however, information concerning lncRNA interplay in multiple myeloma
Autor:
Ludek Pour, David Zihala, Lucie Rihova, Jakub Radocha, Petra Polackova, Miroslav Penka, Jorge J. Castillo, Tereza Sevcikova, Lenka Capkova, Sabina Ševčíková, Tomas Jelinek, Roman Hájek, Zdenka Knechtova, Ondrej Venglar, Renata Bezděková, Martin Stork, Artur Jurczyszyn
Publikováno v:
Blood. 138:546-546
Background: Tumor burden in multiple myeloma (MM) is routinely evaluated in the bone marrow, though its prognostic value is not proven. There is an increasing interest in liquid biopsies due to its minimally invasive nature and more comprehensive eva
Autor:
Lenka Besse, Luděk Pour, Jiri Minarik, Miroslav Penka, Petr Kessler, Sabina Ševčíková, Lucie Brožová, L. Roziakova, Martina Almáši, Renata Bezděková, Jiří Jarkovský, Roman Hájek, Anna Vašků, Petr Pavlicek
Publikováno v:
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 31(3)
Background: Adaptive response to hypoxia is regulated by several mechanisms and transcription factors, including hypoxia-inducible factors (HIFs). Activation of HIF-1α is associated with increased expression of P-glycoprotein and multidrug resistanc
Autor:
Miroslav Penka, Martina Almáši, Luděk Pour, Roman Hájek, Lucie Říhová, Renata Bezděková, Pavla Všianská, Fedor Kryukov
Publikováno v:
European Journal of Haematology. 98:19-25
Background: Aldehyde dehydrogenase (ALDH) is highly active in physiological stem cells as well as in tumor-initiating cells of some malignancies including multiple myeloma (MM). Finding higher activity of ALDH in some cell subsets in monoclonal gammo
Autor:
Roman Hájek, Lucie Říhová, Katerina Growkova, Martin Mistrik, Vladimir Maisnar, Jiri Minarik, Renata Bezděková, Tomas Jelinek, Jana Smejkalová, Alexandra Jungova, Jana Filipova, Fedor Kryukov, Martina Zatopkova, Zuzana Kufova, Tereza Sevcikova, Giovanni Stracquadanio, Michal Simicek, Ludek Pour
Publikováno v:
Blood. 132:3175-3175
Introduction: Multiple myeloma (MM) is a plasma cell dyscrasia causing damage of multiple organs with fatal consequences for patients. Despite the success of modern therapies eliminating a vast bulk of the aberrant cells, surviving residual clones ev
Autor:
Marta Krejčí, Renata Bezděková, Sabina Ševčíková, Zdenek Adam, Jana Gregorová, Roman Hájek, Ludek Pour, Martin Stork, Lenka Sedlarikova, Martina Almáši, David Vrabel
Publikováno v:
Blood. 132:3188-3188
Introduction: Great progress achieved in treatment of multiple myeloma (MM) over the past decade changed overall perception of importance of minimal residual disease (MRD) assessment. Since new drugs induce deep responses, MRD must be evaluated using
Autor:
Sonia Garate, Rafael Del Orbe, Tomas Jelinek, Zuzana Chyra, Michal Simicek, Jesús F. San-Miguel, Renata Bezděková, Xabier Agirre, Lucie Brozova, Cirino Botta, Patricia Maiso, Ludek Pour, Juan José Garcés, María José Calasanz, Alexander Vdovin, Felipe Prosper, Diego Alignani, Laura Blanco, Pamela Millacoy, Roman Hájek, Katerina Growkova, Marco Vicari, Bruno Paiva, Halima El Omri, Leire Burgos, Joaquin Martinez-Lopez, Rafael Rios, Luis Palomera
Publikováno v:
Blood. 132:245-245
Background. The number of CTC predicts risk of transformation in smoldering MM and survival in active MM. Growing evidence suggests that as the tumor progresses and the microenvironment becomes hypoxic, clonal plasma cells (PC) constantly invade new
Autor:
Fedor Kryukov, Tereza Sevcikova, Marian Hajduch, Martina Zatopkova, Zuzana Kufova, Luděk Pour, Lucie Říhová, Renata Bezděková, Jana Filipova, Alexandra Jungova, Petr Vojta, Kateřina Growková, Jana Smejkalová, Roman Hájek, Vladimir Maisnar, Tomas Jelinek, Jiří Minařík, Michal Simicek
Publikováno v:
Klinicka Onkologie. 30:2S75-2S80
Multiple myeloma is a plasma cell dyscrasia. It is the second most common hematological malignancy which is characterized by proliferation of clonal plasma cells producing harmful monoclonal immunoglobulin. Despite treatment modalities greatly evolve